Glenmark Pharmaceuticals has been granted final approval by the FDA for Clindamycin and Benzoyl Peroxide Gel, 1%|5%, a generic version of BenzaClin Gel, 1%|5%, of Valeant Bermuda.
Genmark said in its announcement that, according to IQVIA sales data for the 12 month period ending January 2019, the BenzaClin Gel, 1%|5% market achieved annual sales of approximately $99.4 million.
Glenmark’s current portfolio consists of 151 products authorized for distribution in the U.S. marketplace and 53 ANDA’s pending approval with the U.S. FDA, the company said. In addition to these internal filings, Glenmark said it will work to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.